Page 2 - Nifty Pharma

Wockhardt shares rise 2% after exiting US generics business

Wockhardt shares rose 2 per cent after it decided to exit the US generic pharmaceutical segment after incurring consistent losses

Gland Pharma shares rise on GMP nod for Telangana manufacturing unit

Gland Pharma shares rose 2 per cent after it received a GMP certification from the Danish Medicines Agency for its Telangana plant

Breakout stocks: Nifty Pharma, Biocon, Cipla break over 200-DMA; what next?

The Nifty Pharma index and select shares such as Biocon, Cipla, Zydus Life and Gland Pharma were trading above the respective 200-DMAs after more than 2 months; show technical charts.

Sensex jumps 769 pts, Nifty above 24,850; bulls charge with FMCG, IT stocks

The Sensex settled at 81,721.63, up 769.09 points or 0.95 per cent, while the Nifty50 closed at 24,853.15, gaining 243.45 points or 0.99 per cent.

Mankind Pharma shares slide 3% as Q4 profit declines; details here

Shares of Mankind Pharma dropped over 3 per cent after it posted a 10 per cent fall in consolidated net profit Q4 FY25

Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as investors responded positively to strong Q4 results and favourable FY26 outlook

Dr Reddy's: Brokerage reports by JM Financial, Motilal Oswal as stock up 4%

DRL's management has guided for double-digit growth in FY26, with margins expected to remain similar to FY25 levels. Here's what brokerages expect from the company going ahead

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

Dr Reddy's Q4 results preview: Analysts eye 18% jump in PAT; check details

Dr Reddy's Labs Q4 results 2025 date: Dr Reddy's Laboratories is scheduled to announce its fourth quarter (Q4FY25) results on Friday, May 9, 2025

These 3 pharma stocks have surged over 50% in April; check full list here

A total of 11 pharma and healthcare-related stocks have rallied more than 20% thus far in April on hopes of a likely softer tariff-related stance by the US President Donald Trump.

FIIs buy BFSI, telecom, metal stocks in March 2025; should you too?

Banking, financial services, and insurance (BFSI), telecom, and metals saw the highest FII flows in March 2025

Pharma stocks surge as Trump puts 90-day hold on planned tariffs

Nifty Pharma has fallen by 12.8 per cent so far this year, with Natco Pharma and Granules India leading the plunge

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector

Adding to the worries of investors, US is looking for possible tariffs on the pharmaceutical goods

Nifty Pharma jumps 5% as US exempts reciprocal tariff on pharma goods

All 20 Nifty Pharma constituents settled in the green. Among others, Ipca Laboratories was up 4.59 per cent, Lupin was up 4.19 per cent, Cipla was up 3.28 per cent, Sun Pharma was up 3.41 per cent

Zydus Lifesciences, Granules, Glenmark: Nifty Pharma up despite weak market

Nifty Pharma among others has gained 0.8 per cent in trade, logging an intra-day high at 20,550.6

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

How to trade Nifty Auto, IT, Pharma as Trump threatens up to 25% tariffs

Technical chart suggests that the Nifty Auto, IT and Pharma indices can potentially fall up to 22% from present levels if these key support levels are broken.

Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Time to buy, sell, or hold stocks amid market sell-off? Analyst view here

IT, pharma, cement, and other sectors look attractive to analysts with no pre-budget rally in picture